Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: From experimental models to neurodegenerative diseases

Paolo Gubellini , Barbara Picconi , Massimiliano Di Filippo , Paolo Calabresi

Mitochondrial dysfunctions have been implicated in the cellular processes underlying several neurodegenerative disorders affecting the basal ganglia. These include Huntington's chorea and Parkinson's disease, two highly debilitating motor disorders for which recent research has also involved gene mutation linked to mitochondrial deficits. Experimental models of basal ganglia diseases have been developed by using toxins able to disrupt mitochondrial function: these molecules act by selectively inhibiting mitochondrial respiratory complexes, uncoupling cellular respiration. This in turn leads to oxidative stress and energy deficit that trigger critical downstream mechanisms, ultimately resulting in neuronal vulnerability and loss. Here we review the molecular and cellular downstream effects triggered by mitochondrial dysfunction, and the different experimental models that are obtained by the administration of selective mitochondrial toxins or by the expression of mutant genes.

Mots clés: 3-nitropropionic acid; dopamine; Huntington's chorea; huntingtin; long-term potentiation; parkin; Parkinson's disease; PINK1; rotenone; striatum

Paolo Gubellini, Barbara Picconi, Massimiliano Di Filippo, Paolo Calabresi. Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: From experimental models to neurodegenerative diseases. Biochimica et Biophysica Acta - Molecular Basis of Disease, 2009, 1802 (1), pp.151. ⟨10.1016/j.bbadis.2009.08.001⟩. ⟨hal-00543006⟩